Avalo Therapeutics Inc (AVTX)

Jan 2, 2025, 7:00 AM EST - 15 days ago

Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer

Nov 12, 2024, 7:00 AM EST - 2 months ago

Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants

Nov 11, 2024, 7:00 AM EST - 2 months ago

Avalo Therapeutics to Present at Upcoming Investor Conferences

Oct 8, 2024, 7:00 AM EDT - 3 months ago

Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

Jul 16, 2024, 7:00 AM EDT - 6 months ago

Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer

Jul 9, 2024, 7:00 AM EDT - 6 months ago

Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa

Jun 24, 2024, 4:01 PM EDT - 7 months ago

Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer

Jun 17, 2024, 7:30 AM EDT - 7 months ago

Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit

May 13, 2024, 7:30 AM EDT - 8 months ago

Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates

Apr 2, 2024, 7:00 AM EDT - 10 months ago

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

Apr 1, 2024, 6:02 AM EDT - 10 months ago

Avalo Therapeutics (AVTX) stock slips after earnings: buy the dip?

Mar 29, 2024, 4:01 PM EDT - 10 months ago

Avalo Reports 2023 Financial Results and Provides Business Updates

Mar 27, 2024, 4:01 PM EDT - 10 months ago

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

Dec 27, 2023, 7:00 AM EST - 1 year ago

Avalo Therapeutics Announces 1-for-240 Reverse Stock Split

Dec 7, 2023, 7:00 AM EST - 1 year ago

Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split

Nov 9, 2023, 7:00 AM EST - 1 year ago

Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates

Oct 31, 2023, 7:00 AM EDT - 1 year ago

Avalo Completes Divestiture of AVTX-800 Series

Oct 12, 2023, 11:26 AM EDT - 1 year ago

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

ANVS MTNB TPST

Sep 26, 2023, 7:00 AM EDT - 1 year ago

Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation

Sep 26, 2023, 2:10 AM EDT - 1 year ago

As AVTX stock price soars, Avalo Therapeutics bankruptcy remains

Sep 12, 2023, 7:00 AM EDT - 1 year ago

Avalo Enters into Agreement to Divest AVTX-800 Series

Sep 6, 2023, 7:00 AM EDT - 1 year ago

Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 3, 2023, 7:00 AM EDT - 1 year ago

Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates

Jul 6, 2023, 4:01 PM EDT - 1 year ago

Avalo to Participate in SVB Securities Therapeutics Forum

Jun 26, 2023, 7:00 AM EDT - 1 year ago

Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma

Jun 1, 2023, 7:00 AM EDT - 1 year ago

Avalo to Present at the Jefferies Healthcare Conference

May 22, 2023, 7:00 AM EDT - 1 year ago

Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D.

May 15, 2023, 7:00 AM EDT - 1 year ago

Avalo to Present at ATS 2023 Respiratory Innovation Summit

May 10, 2023, 7:00 AM EDT - 1 year ago

Avalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference

May 4, 2023, 4:01 PM EDT - 1 year ago

Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates

Mar 29, 2023, 7:30 AM EDT - 1 year ago

Avalo Reports 2022 Financial Results and Provides Business Updates

Mar 7, 2023, 7:00 AM EST - 2 years ago

Avalo to Present at Oppenheimer's 33rd Annual Healthcare Conference

Feb 2, 2023, 9:54 PM EST - 2 years ago

Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants

Feb 2, 2023, 4:01 PM EST - 2 years ago

Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants

Jan 17, 2023, 7:00 AM EST - 2 years ago

Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma

Nov 7, 2022, 7:30 AM EST - 2 years ago

Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates

Nov 7, 2022, 7:00 AM EST - 2 years ago

Avalo Sells Economic Rights to Previously Out-Licensed Assets for $5 Million

Sep 6, 2022, 7:00 AM EDT - 2 years ago

Avalo Advances BTLA Agonist Fusion Protein (AVTX-008) to IND-enabling Stage

Sep 1, 2022, 7:00 AM EDT - 2 years ago

Avalo to Present at the H.C. Wainwright Global Investment Conference

Aug 11, 2022, 4:01 PM EDT - 2 years ago

Avalo Therapeutics Announces Board Changes

Aug 4, 2022, 7:30 AM EDT - 2 years ago

Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates

Aug 2, 2022, 7:30 AM EDT - 2 years ago

Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II)

Aug 1, 2022, 7:00 AM EDT - 2 years ago

Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics

Jul 6, 2022, 4:05 PM EDT - 2 years ago

Avalo Therapeutics Announces One-for-Twelve Reverse Stock Split

Jun 2, 2022, 7:30 AM EDT - 2 years ago

Avalo to Present at the 2022 Jefferies Healthcare Conference

May 18, 2022, 7:30 AM EDT - 2 years ago

Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma (NEA)

May 17, 2022, 7:30 AM EDT - 2 years ago

Avalo to Present at the H.C. Wainwright Global Life Sciences Conference

May 5, 2022, 7:30 AM EDT - 2 years ago

Avalo Therapeutics First Quarter 2022 Financial Results and Business Updates

Mar 8, 2022, 7:00 AM EST - 3 years ago

Avalo to Present at Oppenheimer's 32nd Annual Healthcare Conference

Mar 2, 2022, 7:30 AM EST - 3 years ago

Avalo Therapeutics Reports 2021 Financial Results and Provides Business Updates